Related Experiment Video

Updated: Jun 10, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study

Salman Zahoor Bhat1, Jiajun Wu2, Jamie Perin3

  • 1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

The Journal of Clinical Endocrinology and Metabolism
|October 17, 2024
PubMed

Insights

Dexamethasone did not improve survival or clinical improvement for diabetic patients with COVID-19. The study found no increased risk of hyperglycemic emergencies like DKA or HHS in this patient group.

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Patients with diabetes exhibit higher COVID-19 mortality rates.
  • Dexamethasone, a corticosteroid for moderate to severe COVID-19, can exacerbate hyperglycemia.
  • The impact of dexamethasone on diabetic COVID-19 patients requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of dexamethasone in hospitalized COVID-19 patients with diabetes.
  • To compare outcomes between diabetic patients receiving dexamethasone and those not receiving it.

Main Methods:

  • Retrospective analysis of 529 matched pairs of diabetic COVID-19 patients from Johns Hopkins Health System (March 2020 - June 2022).
  • Propensity score matching was used to create comparable groups: dexamethasone users and controls.
  • Cox proportional hazards regression models analyzed outcomes, including 28-day mortality and clinical improvement.

Main Results:

  • No significant difference in 28-day survival rates between dexamethasone and control groups.
  • Time to clinical improvement at 28 days was similar for both groups.
  • Incidence of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) did not differ significantly.

Conclusions:

  • Dexamethasone treatment showed no significant benefit in survival or clinical improvement for diabetic patients with COVID-19.
  • The study did not find an increased risk of severe hyperglycemic events with dexamethasone use in this population.
  • Prospective studies are recommended to confirm these findings and explore underlying mechanisms.
Abstract

Keywords:
COVIDSARS-CoV-2diabetesdiabetic ketoacidosisglucocorticoidshyperglycemiasteroids

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.7K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

204

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
512
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
238
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
152
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
764